Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
was upgraded from Hold to Buy at ISI Group. $43 price target. Company can gain market share and should benefit from an improving employment market.
was initiated with a Neutral rating at UBS. $56 price target. Company likely to see lower sales in its base business.
was started with a Neutral rating at UBS. $66 price target. Company's best growth prospects are still in the pipeline, UBS said.
was upgraded at JMP Securities to Market Outperform. $7 price target. Recent checks with resellers were positive.
was initiated with a Buy rating at UBS. $69 price target. Revlimid should continue to drive the company's growth.
was upgraded from Underperform to Outperform at Oppenheimer. $28 price target. Company should benefit from Medicaid expansion.
was upgraded at Morgan Keegan from Market Perform to Outperform. $75 price target. Sales headwinds should be gone by the end of the year.
downgraded at Ticonderoga from Neutral to Sell. $25 price target. Company is seeing lower organic sales growth.
was initiated with a Buy rating at UBS. $44 price target. Company's HIV franchise should continue to generate significant cash flow, UBS said.
was upgraded at Barclays to Overweight from Equal Weight on higher earnings-growth guidance and strong project backlog. Price target raised to $69 from $66.
( JOYG) was downgraded at Sterne Agee from Buy to Neutral. Valuation call, based on an $82 price target.
Joy Global was downgraded at Morgan Stanley to Underweight. Valuation call, based on a $71 price target.
Joy Global was initiated with a Positive rating at Susquehanna. $91 price target. Company is a best-of-breed operator.
was initiated with a Hold rating at Deutsche Bank. $67 price target. Company still has large exposure to rising commodity costs.
was initiated with a Buy rating at Dahlman Rose. $43 price target. Company should continue to benefit from demand for rare earth metals.
was upgraded at Piper Jaffray to Neutral from Underweight. Valuation call, based on a $3.50 price target.
upgraded at Credit Suisse to Outperform from Neutral. Valuation call, Credit Suisse said. Price target raised to $53 from $45.
This article was written by a staff member of TheStreet.